- Home
- AUID vs IGC Comparison
AUID vs IGC Comparison
Compare AUID & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUID
- IGC
- Stock Information
- Founded
- AUID 2009
- IGC 2005
- Country
- AUID United States
- IGC United States
- Employees
- AUID N/A
- IGC N/A
- Industry
- AUID Computer Software: Prepackaged Software
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- AUID Technology
- IGC Health Care
- Exchange
- AUID Nasdaq
- IGC Nasdaq
- Market Cap
- AUID 47.3M
- IGC 39.8M
- IPO Year
- AUID N/A
- IGC N/A
- Fundamental
- Price
- AUID $3.53
- IGC $0.42
- Analyst Decision
- AUID
- IGC Strong Buy
- Analyst Count
- AUID 0
- IGC 2
- Target Price
- AUID N/A
- IGC $4.00
- AVG Volume (30 Days)
- AUID 50.4K
- IGC 1.4M
- Earning Date
- AUID 11-06-2025
- IGC 08-14-2025
- Dividend Yield
- AUID N/A
- IGC N/A
- EPS Growth
- AUID N/A
- IGC N/A
- EPS
- AUID N/A
- IGC N/A
- Revenue
- AUID $2,189,524.00
- IGC $1,327,000.00
- Revenue This Year
- AUID N/A
- IGC $15.26
- Revenue Next Year
- AUID N/A
- IGC $3.41
- P/E Ratio
- AUID N/A
- IGC N/A
- Revenue Growth
- AUID 295.86
- IGC 24.95
- 52 Week Low
- AUID $3.38
- IGC $0.25
- 52 Week High
- AUID $9.58
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- AUID 37.53
- IGC 57.28
- Support Level
- AUID $3.65
- IGC $0.40
- Resistance Level
- AUID $4.59
- IGC $0.47
- Average True Range (ATR)
- AUID 0.34
- IGC 0.04
- MACD
- AUID -0.06
- IGC 0.00
- Stochastic Oscillator
- AUID 2.75
- IGC 49.20
About AUID authID Inc.
AuthID Inc is a company engaged in ensuring cyber-savvy enterprises Know Who's Behind the Device, for every customer or employee login and transaction. Through its easy-to-integrate, patented, biometric identity platform, authID quickly and accurately verifies a user's identity, eliminating any assumption of who is behind a device and preventing cybercriminals from taking over accounts. authID combines digital onboarding, biometric password less authentication and account recovery, with a fast, accurate, user-friendly experience-delivering identity verification.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.